Recent developments in decision-analytic modelling for economic evaluation.

Abstract:

:The past few years have seen rapid changes in the methods of decision-analytic modelling of healthcare programmes for the purposes of economic evaluation. This paper focuses on four developments in modelling that have emerged over the past few years or have become more widely used. First, no one optimal method for extrapolating outcomes from clinical trials has yet been established. Modellers may draw from a set of varied assumptions about survival extrapolation that encompass a range of possibilities from highly optimistic to extremely cautious. Secondly, the practicality and appeal of microsimulation as a method for analysing healthcare decision problems has increased dramatically with the speed of computing technology. Individual instantiations of a system are generated by using a random process to draw from probability distributions a large number of times (also known as Monte Carlo or probabilistic simulation). Microsimulation is moving in new directions, such as discrete-event simulations that simulate sequences of events by drawing directly from probability distributions of event times; this approach is now being broadly applied to model situations where populations of patients interact with healthcare delivery systems. Microsimulation modelling of transmission systems at the population level is also rapidly developing. Thirdly, model calibration is emerging as a new tool that may offer health scientists a means of generating important fundamental knowledge about disease processes. Model calibration allows evidence synthesis in which observations on observable quantities are used to draw inferences about unobservable quantities. The methodology of model calibration has advanced considerably, drawing on theories of numerical analysis and mathematical programming such as gradient methods, intelligent grid search algorithms, and many more. As a fourth issue, an area of extraordinary activity is in the use of transmission models to analyse interventions for infectious diseases, including population-wide effects of vaccination. Transmission models use differential equations to simulate, deterministically for the most part, transitions among infection-related health states. Only recently have modelling methodologies been combined so that cost-effectiveness analyses can consider explicitly not only the patient-level benefits of interventions but also the secondary benefits through transmission dynamics. Advances in technology allow more realistic and complex healthcare models to be simulated more rapidly. However, decision makers will not readily accept results from models unless they can understand them intuitively and explain them to others in relatively simple terms. The challenge for the next generation of modellers is not only to harness the power available from these newly accessible methods, but also to extract from the new generation of models the insights that will have the power to influence decision makers.

journal_name

Pharmacoeconomics

journal_title

PharmacoEconomics

authors

Weinstein MC

doi

10.2165/00019053-200624110-00002

subject

Has Abstract

pub_date

2006-01-01 00:00:00

pages

1043-53

issue

11

eissn

1170-7690

issn

1179-2027

pii

24112

journal_volume

24

pub_type

杂志文章,评审
  • Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?

    abstract::Which costs and benefits to consider in economic evaluations of healthcare interventions remains an area of much controversy. Unrelated medical costs in life-years gained is an important cost category that is normally ignored in economic evaluations, irrespective of the perspective chosen for the analysis. National gu...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200826100-00003

    authors: Rappange DR,van Baal PH,van Exel NJ,Feenstra TL,Rutten FF,Brouwer WB

    更新日期:2008-01-01 00:00:00

  • Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.

    abstract:OBJECTIVE:To estimate savings in the cost of caring for patients with Alzheimer's disease (AD) during 6 months, 1 year and 2 years of treatment with rivastigmine. An intermediate objective was to estimate the relationship between disease progression and institutionalisation. DESIGN AND SETTING:We assessed the relation...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200017040-00005

    authors: Hauber AB,Gnanasakthy A,Snyder EH,Bala MV,Richter A,Mauskopf JA

    更新日期:2000-04-01 00:00:00

  • Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis.

    abstract::Until a few years ago, griseofulvin and ketoconazole were the only 2 oral agents available for the treatment of dermatophyte onychomycosis of the toenails. With the availability of the newer antifungal agents, such as itraconazole, terbinafine and fluconazole, the armamentarium of drugs available to treat onychomycosi...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199813020-00007

    authors: Gupta AK

    更新日期:1998-02-01 00:00:00

  • Economic and developmental considerations for pharmacogenomic technology.

    abstract::The pharmaceutical industry's core business is the innovation, development and marketing of new drugs. Pharmacogenetic (PG) testing and technology has the potential to increase a drug's value in many ways. A critical issue for the industry is whether products in development should be teamed with genetic tests that cou...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200624040-00004

    authors: Vernon JA,Johnson SJ,Hughen WK,Trujillo A

    更新日期:2006-01-01 00:00:00

  • Barrett's oesophagus: a review of costs of the illness.

    abstract::Barrett's oesophagus is a premalignant complication that occurs in approximately 10% of patients with gastro-oesophageal reflux disease (GORD). In patients with Barrett's oesophagus, the risk of adenocarcinoma of the oesophagus approaches 0.5% per patient-years. Therefore, practice guidelines have been developed that ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200119100-00003

    authors: Arguedas MR,Eloubeidi MA

    更新日期:2001-01-01 00:00:00

  • After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?

    abstract::The National Institute for Health and Care Excellence (NICE) is only one of several organisations internationally that uses economic evaluation as part of decision making regarding funding and pricing of new medical technologies. However, it can be argued that NICE has developed a more prominent international profile ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-019-00882-6

    authors: Sculpher M,Palmer S

    更新日期:2020-03-01 00:00:00

  • Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder.

    abstract:AIM:To assess the relative cost effectiveness of escitalopram compared with venlafaxine XR in patients with major depressive disorder (MDD). METHODS:An economic evaluation was conducted alongside a double-blind, multinational, randomised clinical trial and examined the costs and quality of life of 251 patients taking ...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00019053-200523020-00007

    authors: Fernandez JL,Montgomery S,Francois C

    更新日期:2005-01-01 00:00:00

  • Adherence to guidelines for community-acquired pneumonia: does it decrease cost of care?

    abstract::Community-acquired pneumonia (CAP) is a common diagnosis and care of CAP is responsible for significant healthcare expenditures, the majority of which are for patients who require hospitalisation. Studies have shown that significant variation exists among institutions with respect to antibacterial costs and length of ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200422070-00001

    authors: Brown PD

    更新日期:2004-01-01 00:00:00

  • Translating safety, efficacy and compliance into economic value for controlled release dosage forms.

    abstract::Advanced controlled release (CR) dosage forms are relative newcomers to pharmaceutical markets, and few studies relate their efficacy, safety or compliance benefits to economic value. This literature review was undertaken to assess the cost effectiveness of CR dosage forms using such measures as purchase costs, total ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,meta分析

    doi:10.2165/00019053-199405060-00005

    authors: Cramer MP,Saks SR

    更新日期:1994-06-01 00:00:00

  • Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty.

    abstract::Total hip arthroplasty (THA) is a major orthopaedic procedure with a high risk of postoperative thromboembolism. Increasing demand for this type of surgery, together with its high cost, has led to examination of means by which the cost of THA may be minimised. Current clinical opinion favours the use of suitable pharm...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199610020-00009

    authors: Dunn CJ,Goa KL

    更新日期:1996-08-01 00:00:00

  • The applicability and generalizability of findings from clinical trials for health-policy decisions.

    abstract::Randomized controlled trials provide unbiased estimates of treatment effect through reducing the attribution of observed differences in outcome to the play of chance or the treatment of interest. Issues in the design of randomized trials may lead to a dilution or magnification of treatment effect when compared with cl...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200927010-00002

    authors: Freemantle N,Hessel F

    更新日期:2009-01-01 00:00:00

  • Direct and indirect costs attributable to alcohol consumption in Germany.

    abstract:AIM:To estimate the direct and indirect costs of morbidity and mortality attributable to alcohol consumption in Germany from a societal perspective in 2002. METHODS:Using the concept of attributable risks and the prevalence-based approach, age- and gender-specific alcohol-attributable fractions for morbidity and morta...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200725070-00006

    authors: Konnopka A,König HH

    更新日期:2007-01-01 00:00:00

  • Impact of transformation of negative values and regression models on differences between the UK and US EQ-5D time trade-off value sets.

    abstract:BACKGROUND:National EQ-5D value sets are developed because preferences for health may vary in different populations. UK values are lower than US values for most of the 243 possible EQ-5D health states. Although similar protocols were used for data collection, analytic choices regarding how to model values from the coll...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/11595420-000000000-00000

    authors: Augestad LA,Rand-Hendriksen K,Kristiansen IS,Stavem K

    更新日期:2012-12-01 00:00:00

  • Evaluation of the pharmacoeconomic literature.

    abstract::Pharmacoeconomics identifies, measures, and compares the costs and consequences of pharmaceutical products and services. The cost effectiveness of a pharmacotherapy in a particular indication depends on the molecular configuration of the drug, its safety and efficacy, and local market factors such as the acquisition ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199406040-00002

    authors: Milne RJ

    更新日期:1994-10-01 00:00:00

  • Costs of deep foot infections in patients with diabetes mellitus.

    abstract:OBJECTIVE:To calculate costs for the management of deep foot infections and to identify the most important factors related to treatment costs. DESIGN:Costs for in-hospital care, surgery, investigations, antibacterials, visits to the foot-care team, orthopaedic appliances and topical treatment were calculated retrospec...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200018030-00003

    authors: Tennvall GR,Apelqvist J,Eneroth M

    更新日期:2000-09-01 00:00:00

  • Incorporation of statistical uncertainty in health economic modelling studies using second-order Monte Carlo simulations.

    abstract::Health economic modelling studies are of interest to many parties with different responsibilities and diverging interests. Therefore, it is obvious that recognising the relevance of statistical uncertainty and dealing with it appropriately are required to obtain unbiased results from health economic modelling studies,...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200422120-00001

    authors: Nuijten MJ

    更新日期:2004-01-01 00:00:00

  • A review of the psychometric properties of generic utility measures in multiple sclerosis.

    abstract:OBJECTIVE:The reliability and validity of generic utility measures have not yet been summarized in people with multiple sclerosis (MS). It is important to assess the psychometric properties of these measures, to ensure that the values obtained by the scoring system are valid for interpretation and utilization by clinic...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.1007/s40273-014-0167-5

    authors: Kuspinar A,Mayo NE

    更新日期:2014-08-01 00:00:00

  • On individual preferences and aggregation in economic evaluation in healthcare.

    abstract::For practical reasons, in order to carry out economic evaluations of collective decisions, total costs will generally be compared with total benefits; hence, individuals' willingness to pay (WTP) or quality-adjusted life-years (QALYs) have to be estimated at an aggregate level. So far, aggregation has usually been don...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200119040-00001

    authors: Liljas B,Lindgren B

    更新日期:2001-01-01 00:00:00

  • A parent-child dyad approach to the assessment of health status and health-related quality of life in children with asthma.

    abstract:BACKGROUND:Assessment of health state and health-related quality of life (HR-QOL) are limited by a child's age and cognitive ability. Parent-proxy reports are known to differ from children's reports. Simultaneous assessment using a parent-child dyad is an alternative approach. OBJECTIVE:Our objective was to assess the...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/11597890-000000000-00000

    authors: Ungar WJ,Boydell K,Dell S,Feldman BM,Marshall D,Willan A,Wright JG

    更新日期:2012-08-01 00:00:00

  • Standardisation of costs: the Dutch Manual for Costing in economic evaluations.

    abstract::The lack of a uniform costing methodology is often considered a weakness of economic evaluations that hinders the interpretation and comparison of studies. Standardisation is therefore an important topic within the methodology of economic evaluations and in national guidelines that formulate the formal requirements fo...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200220070-00002

    authors: Oostenbrink JB,Koopmanschap MA,Rutten FF

    更新日期:2002-01-01 00:00:00

  • Measurement of health-related QOL in diabetes mellitus.

    abstract::A number of health-related QOL (HR-QOL) measures specifically designed for people with diabetes mellitus have appeared in the literature. This article provides a selective review of 12 measures that address this important construct. For each included study, a description of the measure and its development phase is pro...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200422170-00002

    authors: Watkins K,Connell CM

    更新日期:2004-01-01 00:00:00

  • Assessing the economic value of a new antidepressant. A willingness-to-pay approach.

    abstract::Using the method of willingness to pay (WTP), this study assesses the value of a new antidepressant, moclobemide, relative to that of tricyclic antidepressants (TCAs), which have equivalent efficacy but less favourable adverse effect profiles. From a published meta-analysis of controlled clinical trials, we identified...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章

    doi:10.2165/00019053-199508010-00006

    authors: O'Brien BJ,Novosel S,Torrance G,Streiner D

    更新日期:1995-07-01 00:00:00

  • The Application and Implications of Novel Deterministic Sensitivity Analysis Methods.

    abstract::Deterministic sensitivity analyses (DSA) remain important to interpret the effect of uncertainties in individual parameters on results of cost-effectiveness analyses. Classic DSA methodologies may lead to wrong conclusions due to a lack of or misleading information regarding marginal effects, non-linearity, likelihood...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-020-00979-3

    authors: Vreman RA,Geenen JW,Knies S,Mantel-Teeuwisse AK,Leufkens HGM,Goettsch WG

    更新日期:2021-01-01 00:00:00

  • Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.

    abstract::Lung cancer remains the leading cause of cancer-related death and economic burden worldwide. Despite the heavy toll of lung cancer, multiple new advances have improved patient outcomes, largely through precision medicine and targeted therapy. The associated rising economic burden however may impact the uptake of novel...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.1007/s40273-017-0563-8

    authors: Albaba H,Lim C,Leighl NB

    更新日期:2017-12-01 00:00:00

  • Parent-proxy EQ-5D ratings of children with attention-deficit hyperactivity disorder in the US and the UK.

    abstract:BACKGROUND:The symptoms of attention-deficit hyperactivity disorder (ADHD) are associated with impairment in multiple domains of health-related quality of life (HR-QOL). HR-QOL of children with ADHD has been assessed by relatively long multidimensional questionnaires. A review of the literature found no studies using t...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200523080-00004

    authors: Matza LS,Secnik K,Mannix S,Sallee FR

    更新日期:2005-01-01 00:00:00

  • Financing Drug Innovation in the US: Current Framework and Emerging Challenges.

    abstract::The current US drug innovation financing framework rests on the notion that a defined period of marketing exclusivity combined with the expectation of reimbursement for clinically valuable, cost-effective therapies, followed by vigorous price competition from generic drugs and biosimilars ensures a sufficient return o...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-020-00926-2

    authors: Cutler D,Kirson N,Long G

    更新日期:2020-09-01 00:00:00

  • Drug use in relation to clinical activities as an instrument for prospective drug budgeting. The Belgian experience.

    abstract::In an effort to control escalating health expenditures, especially in hospitals, many countries are planning or experimenting with prospective budgeting systems. Belgium is no exception and has recently introduced, with some success, limited fixed charges per hospital admission and/or per hospitalisation day for labor...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199609030-00006

    authors: Closon MC,Crott R,Even-Adin D

    更新日期:1996-03-01 00:00:00

  • Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma: in four European countries.

    abstract:OBJECTIVE:Cost is an issue when prescribing two drugs with equivalent efficacy. We compared the direct medical costs of topical brinzolamide 1% (twice a day or three times daily) with topical dorzolamide 2% (twice a day or three times daily) in France, Italy, Portugal and Spain in patients with ocular hypertension or p...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00019053-200321030-00005

    authors: Rouland JF,Le Pen C,Gouveia Pinto C,Berto P,Berdeaux G

    更新日期:2003-01-01 00:00:00

  • Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin's lymphoma.

    abstract::Several randomised comparative trials have shown that granulocyte colony-stimulating factor (G-CSF) reduces the duration of neutropenia, hospitalisation and intravenous antibacterial use in patients with cancer who are receiving high-dosage antineoplastic therapy. However, one area that has received less attention is ...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章

    doi:10.2165/00019053-199711060-00005

    authors: Dranitsaris G,Altmayer C,Quirt I

    更新日期:1997-06-01 00:00:00

  • A stated preference binary choice experiment to explore NICE decision making.

    abstract:OBJECTIVE:To explore whether the National Institute for Health and Clinical Excellence (NICE) takes account of concerns other than just incremental cost effectiveness in commissioning healthcare services. METHOD:A stated preference binary choice experiment was used to explore the preferences of members of NICE's Appra...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200725080-00006

    authors: Tappenden P,Brazier J,Ratcliffe J,Chilcott J

    更新日期:2007-01-01 00:00:00